Look For Institutional Buying In Pacific Biosciences of California Inc (NASDAQ: PACB)

Pacific Biosciences of California Inc (PACB) concluded trading on Tuesday at a closing price of $1.83, with 7.14 million shares of worth about $13.08 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 42.97% during that period and on December 31, 2024 the price saw a gain of about 2.23%. Currently the company’s common shares owned by public are about 273.81M shares, out of which, 241.81M shares are available for trading.

Stock saw a price change of -5.18% in past 5 days and over the past one month there was a price change of -4.19%. Year-to-date (YTD), PACB shares are showing a performance of -81.35% which decreased to -81.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.16 but also hit the highest price of $9.99 during that period. The average intraday trading volume for Pacific Biosciences of California Inc shares is 9.41 million. The stock is currently trading -7.98% below its 20-day simple moving average (SMA20), while that difference is down -8.21% for SMA50 and it goes to -6.27% lower than SMA200.

Pacific Biosciences of California Inc (NASDAQ: PACB) currently have 273.81M outstanding shares and institutions hold larger chunk of about 83.15% of that.

The stock has a current market capitalization of $512.37M and its 3Y-monthly beta is at 1.95. It has posted earnings per share of -$1.46 in the same period. It has Quick Ratio of 8.64 while making debt-to-equity ratio of 2.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PACB, volatility over the week remained 5.50% while standing at 9.25% over the month.

Stock’s fiscal year EPS is expected to drop by -12.49% while it is estimated to increase by 49.72% in next year. EPS is likely to grow at an annualized rate of -1.00% for next 5-years, compared to annual growth of -9.76% made by the stock over the past 5-years.

Coverage by Jefferies stated Pacific Biosciences of California Inc (PACB) stock as a Buy in their note to investors on June 03, 2024, suggesting a price target of $4 for the stock. On April 22, 2024, JP Morgan Downgrade their recommendations, while on April 18, 2024, Goldman Downgrade their ratings for the stock with a price target of $2.50. Stock get an Overweight rating from Stephens on December 14, 2023.

Most Popular

Related Posts